In a tough funding environment, John Maraganore cautions against rushing into founding a company. He recommends that aspiring entrepreneurs first spend 5-10 years at a successful biotech. He argues that when capital is scarce, investors prioritize experienced operators, making deep industry experience a critical prerequisite for getting funded.

CEO Michael Metzger views the high-risk, capital-intensive clinical development phase as a "project" focused on investment and milestones. The organization only transitions into a "business" at the key turning point of drug approval and commercial launch. This mental model helps manage resources and expectations through the long, uncertain pre-commercial journey.

A common failure mode for well-funded biotechs is growing headcount too rapidly. Immunocore's CEO advises new leaders to pace themselves, emphasizing that drug development is a marathon. Prematurely scaling creates fixed expenses that can drain capital before key scientific milestones are hit.

Contrary to the perception that drug development is all about human trials, the first five years of the typical decade-long journey are dedicated to rigorous preclinical work. This foundational stage involves chemistry and non-human testing before a molecule ever reaches a patient.

Drug development can take a decade, a timeframe that misaligns with typical investor horizons and employee careers. Success requires navigating fluctuating capital market cycles and implementing strategies to retain key scientific talent for the long haul.

To attract quality investment, a biotech must present a complete package. A great scientific idea alone is insufficient. It requires initial supporting data to validate the concept and a talented execution-focused team to transform that data into a clinical asset. All three are essential.

The primary obstacle for a new pre-term baby treatment was not just discovery, but mastering a complex protein manufacturing process. This production challenge, where other companies failed, cost Airway Therapeutics $50 million and took five years, highlighting a significant and often underestimated barrier in biotech innovation.

The path for biotech entrepreneurs is a long slog requiring immense conviction. Success ("liftoff") isn't just a clinical trial result, but achieving self-sustaining profitability and growth. This high bar means founders may need to persevere through years of market indifference and financing challenges.

Unlike for-profit ventures driven by rapid ROI, a non-profit biotech's timeline is dictated by maximizing the chances of success. The founder is comfortable if it takes five years just to complete pre-IND submissions, as the primary goal is ensuring the drug gets approved by the FDA, not rushing to market for investors.